Immuron Ltd ADR (IMRN) Stock Analysis

Immuron Ltd ADR (IMRN) is a publicly traded company in the HEALTHCARE sector. It trades at $1.32, carries a market capitalization of $11.51M. This page summarizes the public market data, fundamentals, and frequently asked questions for IMRN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.32
• Market Cap: $11.51M
• EPS: $-0.53
• 52-Week High: $2.39
• 52-Week Low: $0.68

Market Sentiment

Immuron Ltd ADR currently has a Bullish sentiment score of 0.23.

About Immuron Ltd ADR

Immuron Ltd ADR is a biopharmaceutical company dedicated to developing innovative oral immunotherapy solutions harnessing polyclonal antibodies to treat infectious and immunomodulated diseases. Operating globally with research and development activities based in Australia and the United States, Immuron is headquartered in Carlton, Australia. The company is focused on utilizing its proprietary technologies to improve patient outcomes while strategically expanding its product pipeline, position...

GNG Research Analysis

GNG Research scores Immuron Ltd ADR (IMRN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMRN.

Frequently Asked Questions

Does IMRN pay dividends?

Immuron Ltd ADR (IMRN) does not currently pay a regular dividend.

What is IMRN's market cap?

Immuron Ltd ADR (IMRN) has a market capitalization of $11.51M with a current stock price of $1.32.